## Version 1.0.3

## Submission Home > Submission

You can use the options below to view your submission. Where appropriate you can also add to and update your submission and send the details for approval.

Submission Defails	
Status	Accepted
Open Date	01/01/2016
Deadline Date	29/01/2016
Date Submitted	28/01/2016
Туре	Historic Performance In Delivering
NHS provider	Maidstone and Tunbridge Wells NHS Trust

## Showing records 1 to 7 of 7. Pages: 1

69594	69593	69591	69590	69589 .	69588	69587	d Teles
69594 14/WM/1055	69593 15/LO/0691	69591 13/EM/0348	69590 15/LO/0016	69589 14/YH/1237	69588 13/LO/1557	69587 14/NW1258	Research Ethics Committee Reference Number
AB12006 - A prospective, multicentre, randomized, double blind, placebo-controlled, 2-parallel group, phase 3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-flurouracii and folinic acid) to placebo in com	BMS-936558 A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non- Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 133)	Monoprost compared with Lumigan in POA glaucoma/ocular hypertention	MONARCH 3: A Randomised, Double-Bind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) Plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Lo	FLAURA-1 - A phase 111, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Recep	CALM-NET: A Phase 4, Multicentre, Open label, Single Group Exploratory Study to Assess the Clinical Value of Enumeration of Circulating Tumour Cells (CTCs) to Predict Clinical Symptomatic Response and Progression Free Survival in Patients receiving Deep S	ARAMIS 3104007 ORION - A multicentre, randomised, double-blind, placebo-controlled, phase 111 efficacy and safety study of ODM-201 in men with high risk non-metastatic castration-resistant prostate Available cancer.	
Available	Available	Available	Available	Available	Available	Available	Target number of patients available
o	36	10	3	15	2	4	Target number of patients
Available	Available	Available	Available	Available	Available	No Date Agreed With Sponsor	Date Agreed to recruit target number of patients available
01/03/2016	30/04/2016	30/04/2016	30/11/2015	31/03/2016	30/11/2015		Date Agreed to recruit target number of patients
Open	Open	Open	Closed - In Follow Up	Open	Open	Open	Trial Status
N/A	N/A	N/A	Z	N/A	z	N/A	Target met within the agreed time
			Patients screened but not consented and delay in receiving ARSAC certificate for situdy closed to recruitment now		Sponsor delay in activating site. Patients screened no patients consented		Comments

Showing records 1 to 7 of 7. Pages: 1

< Back

